Blogs

Exhibitor-Hosted Programs at the ACT Virtual 41st Annual Meeting

By Art Shaw posted 10-23-2020 06:20 AM

  

 


Be sure to add these Exhibitor-Hosted Programs to your schedule!

Exhibitor-Hosted Programs
(Times listed are in Eastern Standard Time)

Thursday, November 12, 2020

Test Article Conservation in Nonclinical Inhalation Programs
10:00 AM–10:55 AM
Presented by: Covance, Inc.

The Minipig as a Model for Juvenile Toxicity Studies
10:00 AM–10:55 AM
Presented by: Sinclair Research Center, LLC

Challenges to Drug Development in an Evolving International Marketplace: Managing Roadblocks to Success
10:00 AM–10:55 AM
Presented by: WuXi AppTec

Comparison of US FDA and Health Canada CTA Submission to Support First-in-Human (Healthy Normal Subjects) Phase I Clinical Trials
3:00 PM–3:55 PM
Presented by: Altasciences

Use of Duplex Sequencing™ for Detection of In Vivo Mutagenesis as a New Biomarker of Cancer Risk
3:00 PM–3:55 PM
Presented by: MilliporeSigma

Good Laboratory Practice (GLP) Training Session
3:00 PM–3:55 PM
Presented by: Society of Quality Assurance

Friday, November 13, 2020

In Vitro Phenotypic Screening Approaches to Assess Mode of Action and Organ-Specific Toxicity
10:00 AM–10:55 AM
Presented by: Charles River

New Advances in Pharmacokinetic Modeling in Safety Assessment
10:00 AM–10:55 AM
Presented by: Covance, Inc.

Ensuring Good In Silico Practice: Supporting Regulatory Submissions and the Implementation of Protocols
10:00 AM–10:55 AM
Presented by: Leadscope, Inc.—an Instem Company

Reducing the Gap Between (Q)SAR and Expert Review Outcomes
3:00 PM–3:55 PM
Presented by: MultiCASE Inc.

In Vitro ADME and Drug-Drug Interaction Considerations for Toxicologists
3:00 PM–3:55 PM
Presented by: Sekisui XenoTech, LLC


11190 Sunrise Valley Drive, Suite 300, Reston, VA 20191
Tel: 703.547.0875    Fax: 703.438.3113    Email: acthq@actox.org   
Website: www.actox.org    Twitter: @ACToxicology

You may view the ACT Privacy Policy, provide consent to ACT to email you communications, or unsubscribe to stop receiving further ACT communication.
Privacy Policy   |   ProvideConsent   |   Unsubscribe

0 comments
3 views